. Carriers of germline mutations in these genes are at increased risk of developing breast and ovarian cancers. Analysis of BRCA1/BRCA2 in high-risk families has demonstrated considerable heterogeneity in inactivating mutations, with a lower proportion of families attributable to mutations in either gene than had previously been predicted by statistical analyses (Castilla et al, 1994; Phelan et al, 1996; Serova et al, 1997) . We have screened affected individuals from 17 high-risk Welsh breast and breast/ovarian cancer families for mutations in both BRCAJ and BRCA2 to determine the proportion of families attributable to defects in these genes. Recent experience with recurrent BRCAJ and BRCA2 mutations in the Ashkenazi Jewish and Icelandic populations (Neuhausen et al, 1996a; Offit et al, 1996; Thorlacius et al, 1996) , coupled with studies of Welsh cystic fibrosis patients (Ashley, 1986; Cheadle et al, 1993; Lucotte and Hazout, 1995) , suggests that screening for common genetic alterations in patients with familial breast and ovarian cancer in the Welsh population may prove a productive approach to the study of susceptibility in this group.
Two genes, BRCAJ and BRCA2, have been identified as being causative in familial breast/ovarian cancer (Miki et al, 1994; Wooster et al, 1995) . Carriers of germline mutations in these genes are at increased risk of developing breast and ovarian cancers. Analysis of BRCA1/BRCA2 in high-risk families has demonstrated considerable heterogeneity in inactivating mutations, with a lower proportion of families attributable to mutations in either gene than had previously been predicted by statistical analyses (Castilla et al, 1994; Phelan et al, 1996; Serova et al, 1997) . We have screened affected individuals from 17 high-risk Welsh breast and breast/ovarian cancer families for mutations in both BRCAJ and BRCA2 to determine the proportion of families attributable to defects in these genes. Recent experience with recurrent BRCAJ and BRCA2 mutations in the Ashkenazi Jewish and Icelandic populations (Neuhausen et al, 1996a; Offit et al, 1996; Thorlacius et al, 1996) , coupled with studies of Welsh cystic fibrosis patients (Ashley, 1986; Cheadle et al, 1993; Lucotte and Hazout, 1995) , suggests that screening for common genetic alterations in patients with familial breast and ovarian cancer in the Welsh population may prove a productive approach to the study of susceptibility in this group.
PATIENTS AND METHODS
Seventeen families with two or more individuals diagnosed with breast cancer before age 50 years and/or ovarian cancer were selected under informed consent from patients attending the Department of Medical Genetics at the University Hospital of Wales, Cardiff, UK. All families were resident in Wales, with all obviously non-UK names excluded. Pedigrees were obtained by a registered nurse in a face-to-face interview with the patient. Verification of diagnosis was carried out by patient chart and pathology report review wherever possible. All families fulfilling inclusion criteria, who agreed to participate, were reported in the study. All coding exons for BRCAI and BRCA2 were analysed by single-stranded conformation analysis (SSCA) in fragments of 200-300 bp (Miki et al, 1994; Lancaster et al, 1996a) . Genomic DNA was amplified by the polymerase chain reaction (PCR) in a Perkin-Elmer 9600 Thermocycler (Perkin-Elmer, CA, USA). Reaction products were then electrophoresed on 0.5 x MDE (FMC, ME, USA) gels, dried and autoradiographed. Additionally, BRCAI exon 11 and BRCA2 exons 10, 11 and 27 were screened for frameshift and nonsense mutations (producing premature stop codons) using the protein truncation test (PTT) (Lancaster et al, 1996a (Lancaster et al, , 1996b . Exon 11 (BRCAJ) and exons 10 and 27 (BRCA2) were amplified by PCR in one fragment, and exon 11 (BRCA2) in two fragments, in the presence of forward primers containing a T7 promoter and transcription/translation initiation sequence (primer sequences available from jmlanc@acpub.duke.edu). The PCR product was then subjected to an in vitro transcription/translation reaction (Promega, Madison, WI, USA), electrophoresed on a 10-20% sodium dodecyl sulphate (SDS)-polyacrylamide ReadyGel (Biorad, Malvem, PA, USA), fixed, dried and autoradiographed. Sequencing templates were produced for samples showing aberrant mobility on SSCA or PTT and sequenced using a PRISM DyeDeoxy Terminator Cycle Sequencing Kit and an ABI PRIZM 377 Automated Fluorescent Sequencer (Applied BioSystems, CA, USA), according to manufacturer's instructions. Genotyping was carried out using fluorescent dye-labelled primer pairs analysed on the ABI377 with the Genescan software package. Sequences of primers are available from the Genome The results show that, overall, only approximately half of these families were found to be segregating either a BRCAJ or BRCA2
mutation. This proportion, although lower than that predicted by statistical analysis of a cohort of families collected for the linkage analysis, is in agreement with that observed in several other studies. Interestingly, recurrent mutations were observed in half of the families with mutations, all of whom appear to be unrelated.
Families CDF2 and CDF7 were found to have a BRCAJ 4184de14 mutation, whereas families CDF13 and CDF128 were found to have a BRCAJ 2594delC mutation. DNA samples from the recurrent mutation carriers were genotyped for a series of polymorphic microsatellite markers in and flanking BRCAJ to assess haplotype sharing which would be indicative of common founder effects for these two mutations ( (1998) 78(11), [1417] [1418] [1419] [1420] . Cancer Research Campaign 1998
BRCAl and BRCA2 in Wales 1419 from unaffected Welsh control subjects and appears to be quite rare in this population (unpublished results). Other studies have also reported a Dl 7S855 157-bp allele in association with the 4184de14 mutation . However, in those families, a 11 8-bp allele at the adjacent intragenic marker D 17S 1322 has been reported, whereas CDF2 and CDF7 share a 121-bp D17S1322 allele in disequilibrium with the D17S855 allele. The 4184de14 mutation has been reported 14 times in individuals of various ethnic backgrounds, and appears to be segregating on at least two different haplotypes to which our data from Wales adds a third (Neuhausen et al, 1996b; Szabo and King, 1997) . Two other families, CDF 13 and CDF128, were found to be carrying a common 2594delC BRCAJ mutation. Genotyping revealed a common haplotype for this mutation as well. An additional marker centromeric to BRCAI, D17S1185, was also typed to confirm allele sharing proximal to the ambiguous genotype at Dl 7S1320. This mutation has also been reported frequently in Sweden and Denmark (Johannsson et al, 1996; Hakansson et al, 1997) , with those families reported to share a common allele of D17S855, and has also been reported once in a family from the south of England (Campbell et al, 1997) . As is the case for the BRCAJ 4184de14 mutation, data for the BRCAJ 2594delC mutation indicates that it is also probably a recurrent founder mutation in the Welsh population. Full genealogical tracing is ongoing for all families with recurrent mutations. Additionally, we hope to obtain DNA from other members of family CDF128 to assess BRCAI mutation status in individuals affected with uterine, lung and testicular carcinoma. This study suggests that screening for the two recurrent BRCAJ mutations described here may be a useful first step in assessing Welsh hereditary breast/ovarian cancer families. The mutation detection rate in this cohort compares favourably with families ascertained in other studies (Phelan et al, 1996; Szabo and King, 1997) . The proportion of breast cancer families attributable to BRCAJ and BRCA2 mutations in this cohort is roughly similar to that described elsewhere in Britain (Szabo and King, 1997) . However, the finding of only one of five breast/ovarian families with BRCA] mutations is less than has been reported elsewhere (Narod et al, 1995) . Additionally, we failed to detect any instances of the 6503delTT mutation in BRCA2 that has been seen frequently in British families (Mazoyer et al, 1996) . These data support the observation that although the overall contribution of BRCAJ/BRCA2 to familial breast cancer may be the same among study groups, the distribution of mutations is quite variable with respect to ethnogeographical differences. BRCA] mutation detection sensitivity using SSCA alone is approximately 80% (Lancaster et al, 1997) , and our detection rate in this study is probably increased by the additional use of the protein truncation test (PTT). However, even if SSCA and PTT together fail to identify 15% of mutations, our data still provide support for the view that a significant proportion of familial breast/ovarian cancer (approximately 35-53%) is not due to mutations in either BRCAJ or BRCA2, and that other dominant breast cancer susceptibility genes may exist. Linkage analysis of families negative for BRCAJ and BRCA2 mutations would further support this philosophy, and we are currently collecting samples from other family members wherever possible. The finding of BRCA I mutations in only one out of five breast/ovarian cancer families suggests additional familial ovarian cancer gene(s) also exist. Patients tested for BRCA1 and BRCA2 mutations and found to be negative should, thus, be informed of the potential of mutations in other as yet unidentified breast and ovarian cancer susceptibility genes contributing to continued increased cancer risk.
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